Insights
Search Results
News Articles
6.03.26
Jason Breen Honored Among LABJ's "Leaders of Influence: M&A"
On June 1, 2026, Wilson Sonsini partner Jason Breen was named among Los Angeles Business Journal's 2026 "Leaders of Influence: M&A." The annual supplement recognizes the LA region's top M&A experts and thought leaders for their leadership, skill, and achievements in the realm of M&A.
Client Highlights
3.30.26
Wilson Sonsini Advises Octopus Energy on Majority Stake Acquisition of Uplight
On March 24, 2026, Octopus Energy Group, a global clean energy and technology business driving the affordable, green energy system of the future, will cement its expansion in the U.S. by acquiring a majority stake in Uplight, a leading provider of customer engagement and flexibility management solutions that rapidly transform customer participation into dependable grid capacity. The deal is made in partnership with Schneider Electric, a global energy technology leader trusted by utilities worldwide, which will remain as a significant minority partner. The transaction is subject to customary regulatory approvals and is expected to complete later this year. Wilson Sonsini Goodrich & Rosati advised Octopus Energy on the transaction.
Case Studies
2.24.26
How Wilson Sonsini Helped Foresight Diagnostics with Its Growth, Scale-Up, and Acquisition
Foresight Diagnostics is a leading cancer diagnostics company founded in 2020 and spun out of Stanford University. Foresight has developed a novel liquid biopsy testing platform for the measurement of minimal residual disease that is significantly more sensitive than existing tests. Its technology, called PhasED-SeqTM, is based on a simple blood draw and next-generation sequencing. It is broadly applicable to a variety of cancers, and its ability to detect circulating tumor DNA at levels of 0.0001 percent (or one part-per-million) has the potential to provide actionable information to physicians and biopharmaceutical companies, thus enabling the development of a more proactive and personalized treatment approach.
Client Highlights
11.26.25
Wilson Sonsini Advises Dayra Therapeutics on Strategic Collaboration with Biogen Inc.
On November 24, 2025, Dayra Therapeutics, a start-up focused on developing oral macrocyclic peptide therapeutics to treat a range of human diseases, announced a research collaboration with Biogen Inc.
Client Highlights
10.17.25
Wilson Sonsini Advises Omeros on Asset Purchase and License Agreement with Novo Nordisk
On October 15, 2025, Novo Nordisk and Omeros Corporation announced that they have entered into a definitive asset purchase and license agreement for the candidate drug zaltenibart (OMS906) in clinical development for rare blood and kidney disorders. Wilson Sonsini Goodrich & Rosati advised Omeros on the transaction.
Client Highlights
3.18.25
Wilson Sonsini Advises DispatchHealth on Merger with Medically Home
On March 18, 2025, DispatchHealth, a leading provider of high-acuity, in-home medical care for people experiencing serious health concerns, and Medically Home, an established hospital-at-home technology enablement model for health systems and physician groups to safely provide emergency and hospital-level care at home for qualified patients, announced that they have entered into a definitive agreement to merge. The merger creates the country's most comprehensive provider of advanced medical care at home. Wilson Sonsini Goodrich & Rosati advised DispatchHealth on the transaction.
Once the deal closes, Medically Home will become part of DispatchHealth. The combined entity will extend care into the homes of patients across 50 major metropolitan areas in partnership with nearly 40 health systems, as well as most major health plans and value-based care entities. The merger is expected to close mid-year 2025, subject to customary closing conditions and regulatory approvals.
The Wilson Sonsini team that advised DispatchHealth on the transaction included Jason Breen, Matt Dubofsky, Brian Chan, and Leah Hengemuhle.
For more information, please see the companies’ news release.
Once the deal closes, Medically Home will become part of DispatchHealth. The combined entity will extend care into the homes of patients across 50 major metropolitan areas in partnership with nearly 40 health systems, as well as most major health plans and value-based care entities. The merger is expected to close mid-year 2025, subject to customary closing conditions and regulatory approvals.
The Wilson Sonsini team that advised DispatchHealth on the transaction included Jason Breen, Matt Dubofsky, Brian Chan, and Leah Hengemuhle.
For more information, please see the companies’ news release.
Client Highlights
3.17.25
Firm Advises Taiho Pharmaceutical on Acquisition of Araris Biotech for Up to $1.1 Billion
On March 17, 2025, Taiho Pharmaceutical Co., Ltd., an R&D-driven specialty pharmaceutical company focusing on the fields of oncology and immune-related diseases, and Araris Biotech AG, a Swiss biotechnology company developing next-generation antibody drug conjugates (ADCs), announced that they have entered into a definitive agreement pursuant to which Taiho Pharmaceutical will acquire Araris. Under the terms of the agreement, Taiho Pharmaceutical will pay $400 million at closing, with the potential for additional milestone payments of up to $740 million. The acquisition, which is expected to be completed in the first half of 2025, follows a research collaboration between Taiho Pharmaceutical and Araris signed in November 2023. Wilson Sonsini Goodrich & Rosati advised Taiho Pharmaceutical on the acquisition.
Araris is a spin-off company of the Paul-Scherrer-Institute in Switzerland and is pioneering the development of best-in-class ADCs with superior design, high linker solubility, and simple manufacturing that address the shortcomings of current generation ADCs. Taiho Pharmaceutical, in addition to antimetabolites, has established and created novel drugs through its proprietary small molecule drug discovery platform, Cysteinomix, enhancing cancer treatment and contributing to patient care. By acquiring Araris' innovative ADC drug discovery technology platform, Taiho Pharmaceutical will further expand its ongoing development portfolio in the field of oncology.
The Wilson Sonsini team that advised Taiho Pharmaceutical on the transaction included Miranda Biven, Jason Breen, Nellie Brutocao, and Ken Clark.
For more information, please see the companies’ joint news release. Additional coverage is available on Fierce Biotech and BioSpace.
Araris is a spin-off company of the Paul-Scherrer-Institute in Switzerland and is pioneering the development of best-in-class ADCs with superior design, high linker solubility, and simple manufacturing that address the shortcomings of current generation ADCs. Taiho Pharmaceutical, in addition to antimetabolites, has established and created novel drugs through its proprietary small molecule drug discovery platform, Cysteinomix, enhancing cancer treatment and contributing to patient care. By acquiring Araris' innovative ADC drug discovery technology platform, Taiho Pharmaceutical will further expand its ongoing development portfolio in the field of oncology.
The Wilson Sonsini team that advised Taiho Pharmaceutical on the transaction included Miranda Biven, Jason Breen, Nellie Brutocao, and Ken Clark.
For more information, please see the companies’ joint news release. Additional coverage is available on Fierce Biotech and BioSpace.
Client Highlights
10.02.24
Wilson Sonsini Advises Pure Lithium on Asset Acquisition of Dimien
On October 1, 2024, Pure Lithium Corporation, a disruptive Boston-based vertically integrated lithium metal battery technology company, announced the acquisition of all the assets of Dimien Inc., a private U.S. vanadium cathode materials company. Pure Lithium acquired Dimien’s intellectual property, know-how, and manufacturing equipment. Dimien's experienced team will also join the company. Wilson Sonsini Goodrich & Rosati advised Pure Lithium on the transaction.
Client Highlights
9.26.24
Wilson Sonsini Advises Vertos Medical Inc. in Acquisition by Stryker
On August 22, 2024, Stryker, a global leader in medical technologies, announced a definitive agreement to acquire Vertos Medical Inc., a privately held company providing a minimally invasive solution for treating chronic lower back pain caused by lumbar spinal stenosis. Wilson Sonsini Goodrich & Rosati advised Vertos on the transaction.
Client Highlights
8.23.24
Wilson Sonsini Advises Borealis Biosciences on $150 Million Series A and Strategic Collaboration Funding
On August 22, 2024, Borealis Biosciences (Borealis), a next-generation RNA medicines company, emerged from stealth with $150 million in combined Series A financing from founding investor Versant Ventures and Novartis AG, as well as committed strategic research collaboration funding from Novartis. Wilson Sonsini Goodrich & Rosati advised Borealis on the transaction.
Client Highlights
1.02.24
Firm Advises Replace Therapeutics on Acquisition by Tome Biosciences
On January 2, 2024, Tome Biosciences, Inc., a programmable genomic integration (PGI) company, announced that it has acquired Replace Therapeutics Inc., a private biotechnology company developing a novel PGI method capable of inserting and deleting small DNA sequences. Wilson Sonsini Goodrich & Rosati advised Replace Therapeutics on the transaction.
Replace Therapeutics’ technology combines the site-specificity of CRISPR/Cas9 with the writing enzyme DNA ligase to precisely manipulate small DNA sequences. This ligase-mediated PGI (L-PGI) technology is well-suited for tens to hundreds of base pair DNA edits, complementing Tome’s flagship large DNA PGI technology, integrase-mediated PGI (I-PGI). In in vitro studies, L-PGI has demonstrated high efficiency and specificity in both dividing and non-dividing cells without the need for double-strand DNA breaks.
Under the terms of the acquisition, Tome will acquire Replace Therapeutics through a merger transaction of $65 million in up-front and near-term milestones, and a total deal value of up to $185 million through a mix of stock and cash. As a result of the merger, Replace Therapeutics will be a wholly owned subsidiary of Tome Biosciences.
The Wilson Sonsini team that advised Replace Therapeutics on the transaction included James Huie, Jason Breen, and Vishakha Negi.
For more information, please see Tome’s news release. Additional coverage is available in Endpoints News.
Replace Therapeutics’ technology combines the site-specificity of CRISPR/Cas9 with the writing enzyme DNA ligase to precisely manipulate small DNA sequences. This ligase-mediated PGI (L-PGI) technology is well-suited for tens to hundreds of base pair DNA edits, complementing Tome’s flagship large DNA PGI technology, integrase-mediated PGI (I-PGI). In in vitro studies, L-PGI has demonstrated high efficiency and specificity in both dividing and non-dividing cells without the need for double-strand DNA breaks.
Under the terms of the acquisition, Tome will acquire Replace Therapeutics through a merger transaction of $65 million in up-front and near-term milestones, and a total deal value of up to $185 million through a mix of stock and cash. As a result of the merger, Replace Therapeutics will be a wholly owned subsidiary of Tome Biosciences.
The Wilson Sonsini team that advised Replace Therapeutics on the transaction included James Huie, Jason Breen, and Vishakha Negi.
For more information, please see Tome’s news release. Additional coverage is available in Endpoints News.
Client Highlights
12.18.23
Wilson Sonsini Advises OhmConnect on Merger Agreement with Google Nest Renew
On December 14, 2023, Google Nest Renew, a load shifting service for Google Nest thermostats that help customers shift their energy usage to times when the electrical grid is cleaner or energy is less expensive, announced that it is spinning out from Google and combining with OhmConnect, a start-up that Sidewalk Infrastructure Partners (SIP) invests in that helps manage load shifting services for Nest and other smart thermostat brands. The new company will be called "Renew Home." Wilson Sonsini Goodrich & Rosati is advising OhmConnect on the transaction.
SIP will combine their platform company, OhmConnect, with assets from Google Nest’s Renew service business to form Renew Home, which will help customers and energy providers unlock energy savings and rewards in a way that supports a clean energy grid. Renew Home will combine OhmConnect’s innovative home energy management platform, which has helped California avoid dangerous blackouts, with Google Nest’s leadership in energy products and services that help customers prioritize cheaper and cleaner energy. Nest Renew and OhmConnect customers will have improved experiences and offerings, as Renew Home works with partners across the energy industry to offer savings and rewards while accelerating the clean energy transition. SIP is also investing $100 million in fresh capital to drive Renew Home’s future growth as a SIP platform company. The closing of the transaction is subject to regulatory approvals and other customary closing conditions.
SIP will combine their platform company, OhmConnect, with assets from Google Nest’s Renew service business to form Renew Home, which will help customers and energy providers unlock energy savings and rewards in a way that supports a clean energy grid. Renew Home will combine OhmConnect’s innovative home energy management platform, which has helped California avoid dangerous blackouts, with Google Nest’s leadership in energy products and services that help customers prioritize cheaper and cleaner energy. Nest Renew and OhmConnect customers will have improved experiences and offerings, as Renew Home works with partners across the energy industry to offer savings and rewards while accelerating the clean energy transition. SIP is also investing $100 million in fresh capital to drive Renew Home’s future growth as a SIP platform company. The closing of the transaction is subject to regulatory approvals and other customary closing conditions.